A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF THE MTOR KINASE INHIBITOR CC-223 IN COMBINATION WITH ERLOTINIB OR ORAL AZACITIDINE IN ADVANCED NON-SMALL CELL LUNG CANCER

Trial Profile

A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF THE MTOR KINASE INHIBITOR CC-223 IN COMBINATION WITH ERLOTINIB OR ORAL AZACITIDINE IN ADVANCED NON-SMALL CELL LUNG CANCER

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2016

At a glance

  • Drugs Azacitidine (Primary) ; CC 223 (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 08 Jul 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 25 Nov 2014 Planned End Date changed from 1 Mar 2015 to 1 Dec 2015, according to ClinicalTrials.gov record.
    • 25 Nov 2014 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top